New Year, Ready to Restart Your Trial? | Veeva
Summary
When defining your strategy for managing missing data and performing mid-study amendments there are technology challenges to navigate. Study amendments in Vault EDC can be rapidly deployed and do not require data migration or downtime. Therefore if you do choose to update your protocol design, e.g. stop collecting data for exploratory endpoints, you can achieve this amendment in EDC with simplicity and speed. Veeva Vault EDC equips companies to respond faster to changes and new demands, contact us to learn more. a – FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency Guidance for Industry, Investigators, and Institutional Review Boards March 2020 b – EMA, Points to consider on implications of Coronavirus disease 5 (COVID-19) on methodological aspects of ongoing clinical 6 trials